Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

ABSTRACT:

Background

Many prognostic markers have been identified in chronic lymphocytic leukemia, but there have been few opportunities to assess their relative importance in a large randomized trial. The aim of this study was to determine which of the available markers independently predicted outcome in patients requiring treatment and to use these to define new risk groups.

Design and methods

A broad panel of clinical and laboratory markers, measured at randomization in patients entering the LRF CLL4 trial, was assessed with respect to treatment response, progression-free and overall survival, at a median follow-up of 68 months.

Results

Using the factors identified as independent predictors for progression-free survival, patients were subdivided into three risk groups: 6% ha

SUBMITTER: Oscier D 

PROVIDER: S-EPMC2948096 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature